Metraipolis › archive › dc_28e7835c3d4e

Different Trends of Immune Activation Markers When Switching to Either Oral or Injectable Dual Antiretroviral Therapy Based on Integrase Inhibitors in People… — Europe PMC PMID:41901769

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41901769
DOI
10.3390/pathogens15030316
License (as archived)
solo-consultazione
Archived
2026-11-04T09:34:37.538Z
SHA-256 of the archived text
702bbab58b5b3ffd2161796d9e922696aade66287a89d7ea5b836805b3fba55a
Stable URL of this page
https://metraipolis.com/documento/dc_28e7835c3d4e

How to cite

Different Trends of Immune Activation Markers When Switching to Either Oral or Injectable Dual Antiretroviral Therapy Based on Integrase Inhibitors in People… — Europe PMC PMID:41901769 — Europe PMC (en), https://europepmc.org/article/MED/41901769 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_28e7835c3d4e (Metraipolis archive dc_28e7835c3d4e, sha256 702bbab58b5b3ffd2161796d9e922696aade66287a89d7ea5b836805b3fba55a)
BibTeX
@misc{dc28e7835c3d4e,
  title = {Different Trends of Immune Activation Markers When Switching to Either Oral or Injectable Dual Antiretroviral Therapy Based on Integrase Inhibitors in People… — Europe PMC PMID:41901769},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41901769},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_28e7835c3d4e; sha256 702bbab58b5b3ffd2161796d9e922696aade66287a89d7ea5b836805b3fba55a},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41901769. Agents can read the archived copy with the MCP tool read_document.